Studies on the pathogenesis and anti-VEGF treatment of retinopathy of prematurity

收集了11例ROP婴儿的血清样本，这些婴儿在注射前、注射后1天、1周和2周接受了贝伐单抗玻璃体内注射。采用酶联免疫吸附法测定血清贝伐单抗和VEGF浓度。结果，贝伐珠单抗玻璃体内注射0.5 mg前、1天、1周、2周的血清浓度分别为0、195、946L、1214 （ng/mL）。静脉注射贝伐单抗0.5 mg前、1天、1周、2周血清VEGF浓度分别为1628、427、246、269 （pg/mL）。血清贝伐单抗浓度与VEGF呈显著负相关（r= 0.575， P=0.0125）。这些结果表明，贝伐单抗可以从眼睛进入体循环，降低ROP婴儿的血清VEGF水平。

Serum samples were collected from 11 infants with ROP who had received intravitreal bevacizumab injection before and 1 day, 1 week, and 2 weeks after the injection. The serum concentrations of bevacizumab and VEGF were measured by enzyme-linked immunosorbent assay. As a result, the serum concentration of bevacizumab before and 1 day, 1week, and 2 weeks after a total of 0.5 mg of intravitreal bevacizumab was 0, 195, 946L, and 1214 (ng/mL), respectively. The serum concentration of VEGF before and 1 day, 1 week, and 2 weeks after a totalof 0.5 mg intravitreal bevacizumab was 1628, 427, 246, and 269 (pg/mL), respectively. There was a significant negative correlation (r= 0.575, P=0.0125) between the serum concentration of bevacizumab and VEGF. These results indicate that bevacizumab can escape from the eye into the systemiccirculation and reduce the serum level of VEGF in infants with ROP.